Premium
Evaluation of corrosion resistance of implant‐use Ti‐Zr binary alloys with a range of compositions
Author(s) -
Akimoto Teisuke,
Ueno Takeshi,
Tsutsumi Yusuke,
Doi Hisashi,
Hanawa Takao,
Wakabayashi Noriyuki
Publication year - 2018
Publication title -
journal of biomedical materials research part b: applied biomaterials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.665
H-Index - 108
eISSN - 1552-4981
pISSN - 1552-4973
DOI - 10.1002/jbm.b.33811
Subject(s) - materials science , corrosion , alloy , zirconium , zirconium alloy , dissolution , metallurgy , titanium , chloride , metal , pitting corrosion , biocompatibility , lactic acid , nuclear chemistry , chemical engineering , chemistry , engineering , biology , bacteria , genetics
Abstract Although titanium‐zirconium (Ti‐Zr) alloy has been adopted for clinical applications, the ideal proportion of Zr in the alloy has not been identified. In this study, we investigated the biocompatibility of Ti‐Zr alloy by evaluating its corrosion resistance to better understand whether there is an optimal range or value of Zr proportion in the alloy. We prepared pure Ti, Ti‐30Zr, Ti‐50Zr, Ti‐70Zr, and pure Zr (mol% of Zr) samples and subjected them to anodic polarization and immersion tests in a lactic acid + sodium chloride (NaCl) solution and artificial saliva. We observed pitting corrosion in the Ti‐70Zr and Zr after exposure to both solutions. After the immersion test, we found that pure Ti exhibited the greatest degree of dissolution in the lactic acid + NaCl solution, with the addition of Zr dramatically reducing Ti ion dissolution, with the reduction ultimately exceeding 90% in the case of the Ti‐30Zr. Hence, although the localized corrosion resistance under severe conditions was compromised when the Zr content was more than 70%, metal ion release reduced owing to Zr addition and the corresponding formation of a stable passive layer. The results suggest that Ti‐30Zr or a Zr proportion of less than 50% would offer an ideal level of corrosion resistance for clinical applications. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 73–79, 2018.